Vitamin E: tocopherols and tocotrienols as potential radiation countermeasures

• Published in: Journal of radiation research Vol. 54; no. 6; pp. 973 - 988
• Main Authors: Singh, Vijay K., Beattie, Lindsay A., Seed, Thomas M.
• Format: Journal Article
• Language: English
• Published: England Oxford University Press 01.11.2013
• Subjects: Acute Radiation Syndrome - physiopathology; Acute Radiation Syndrome - prevention & control; Analysis; Animals; Antioxidants; Countermeasures; Critical Care - methods; Derivatives; Drug approval; Effectiveness; Free radicals; Humans; Ionizing radiation; Mathematical models; Radiation Protection - methods; Radiation-Protective Agents - therapeutic use; Radiotherapy; Review; Tocopherol; Tocopherols; Tocopherols - therapeutic use; Tocotrienols - therapeutic use; Treatment Outcome; Vitamin E; Vitamin E - therapeutic use; tocotrienols; Countermeasures; tocopherols; radiation; mice; vitamin E
• ISSN: 0449-3060; 1349-9157
• DOI: 10.1093/jrr/rrt048

Despite the potential devastating health consequences of intense total-body irradiation, and the decades of research, there still remains a dearth of safe and effective radiation countermeasures for emergency, radiological/nuclear contingencies that have been fully approved and sanctioned for use by the US FDA. Vitamin E is a well-known antioxidant, effective in scavenging free radicals generated by radiation exposure. Vitamin E analogs, collectively known as tocols, have been subject to active investigation for a long time as radioprotectors in patients undergoing radiotherapy and in the context of possible radiation accidents or terrorism scenarios. Eight major isoforms comprise the tocol group: four tocopherols and four tocotrienols. A number of these agents and their derivatives are being investigated actively as radiation countermeasures using animal models, and several appear promising. Although the tocols are well recognized as potent antioxidants and are generally thought to mediate radioprotection through 'free radical quenching', recent studies have suggested several alternative mechanisms: most notably, an 'indirect effect' of tocols in eliciting specific species of radioprotective growth factors/cytokines such as granulocyte colony-stimulating factor (G-CSF). The radioprotective efficacy of at least two tocols has been abrogated using a neutralizing antibody of G-CSF. Based on encouraging results of radioprotective efficacy, laboratory testing of -tocotrienol has moved from a small rodent model to a large nonhuman primate model for preclinical evaluation. In this brief review we identify and discuss selected tocols and their derivatives currently under development as radiation countermeasures, and attempt to describe in some detail their in vivo efficacy.